Intrahepatic Cholestasis of Pregnancy Increases Inflammatory Susceptibility in Neonatal Offspring by Modulating Gut Microbiota

Qiongxi Lin, Wan-wen Huang, Wei Shen, Xiaoshi Deng, Ziyu Tang, Zhenhui Chen, Wei Zhao, Hongying FanFrontiers in Immunology 2022 · DOI

TL;DR

Maternal intrahepatic cholestasis of pregnancy (ICP)—characterized by high bile acid levels—primes neonatal offspring for increased inflammatory susceptibility. This study reveals that elevated intrauterine bile acids alter the offspring's gut microbiota and trigger a compensatory over-activation of the farnesoid X receptor (FXR), which can be mitigated by specific probiotic supplementation.

What Problem Does This Paper Address?

Intrahepatic cholestasis of pregnancy (ICP) is a common liver disorder affecting pregnant women, primarily marked by elevated maternal serum bile acids (BAs). While researchers have long known that ICP is linked to adverse fetal outcomes and long-term metabolic issues in offspring, the impact on the neonatal immune system remained a "black box."

The authors sought to determine if and how maternal cholestasis predisposes newborns to inflammatory disorders. Specifically, they investigated the interplay between bile acid metabolism, the gut microbiome, and the farnesoid X receptor (FXR)—a nuclear receptor that regulates bile acid homeostasis and, as it turns out, plays a significant role in intestinal immunity.

Methods

The researchers employed a dual-track approach combining human clinical data with a controlled animal model:

  1. Human Cohort Study: A retrospective analysis of 134 neonates (71 from ICP mothers, 63 from healthy controls) to correlate maternal bile acid levels with neonatal clinical outcomes like infection rates and blood cell counts.
  2. Rat Model of ICP: Pregnant Sprague-Dawley rats were fed a 0.5% cholic acid (CA) diet to mimic ICP. Their offspring were then studied for metabolic and immunological changes.
  3. Microbiome & Metabolomics: The team used 16S rRNA sequencing to profile the gut microbiota and UPLC-MS/MS to analyze fecal bile acid composition.
  4. Immunological Challenges: Neonatal rats were exposed to lipopolysaccharide (LPS) to induce an inflammatory response.
  5. Pharmacological & Probiotic Intervention: To pinpoint the mechanism, they used an FXR agonist (GW4064), an FXR antagonist (E/Z-GS), and a specific probiotic strain (Lactobacillus rhamnosus LRX01) known to inhibit ileal FXR expression.

Datasets

  • Clinical Dataset: Hospital records from Nanfang Hospital (2014–2021) including maternal total bile acid (TBA) levels and neonatal blood infection markers (CRP, PCT, IL-6).
  • Microbiota Data: 16S rRNA gene sequences from neonatal rat cecal contents (deposited in NCBI BioProject PRJNA812501).
  • Metabolomic Data: Targeted bile acid profiles from neonatal rat feces.

Key Insights and Ideas

  • The "Compensatory Activation" Trap: In the first week of life, ICP offspring showed an initial reduction in FXR expression followed by a massive compensatory surge. This over-activation of FXR in the ileum (the end of the small intestine) was directly linked to increased inflammatory signaling.
  • Microbial Dysbiosis: ICP offspring had a significantly higher relative abundance of Escherichia-Shigella, a genus often associated with pathogenicity and inflammation. This suggests that maternal bile acids "program" the initial microbial colonization of the gut.
  • FXR as an Immune Rheostat: The study demonstrates that FXR isn't just for metabolism; it regulates the NLRP3 inflammasome and Th17 cell (RORγ-T) pathways. Over-active FXR in the gut makes the offspring hyper-responsive to inflammatory triggers like LPS.
  • Probiotic Rescue: Perhaps the most exciting insight is that Lactobacillus rhamnosus LRX01 can act as a natural FXR inhibitor. By dampening the over-active FXR, the probiotic reduced the offspring's susceptibility to inflammation-induced mortality.

Key Results

  • Human Findings: Neonates from ICP mothers had significantly higher rates of infection (28.2% vs. 11.1%) and jaundice (84.5% vs. 66.7%) compared to controls. Maternal TBA levels were negatively correlated with neonatal platelet and monocyte counts.
  • Animal Survival: In the LPS challenge, ICP offspring had a significantly higher mortality rate than control offspring.
  • Cytokine Surge: ICP offspring exhibited much higher levels of pro-inflammatory cytokines (IL-1β and TNF-α) in both serum and ileal tissue following LPS exposure.
  • Intervention Success: Treatment with the FXR antagonist E/Z-GS or the probiotic LRX01 significantly decreased the expression of pro-inflammatory markers and improved survival rates in the rat model.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Nature: The human data was retrospective; a prospective study would be needed to more firmly establish causality and control for all neonatal hospital variables.
  • Early-Stage Focus: The study focused on the first week of life. It remains unclear if this inflammatory "priming" persists into adulthood or if the immune system eventually recalibrates.
  • Mechanism Specificity: While LRX01 inhibits FXR, it likely has other beneficial effects on the gut barrier and immune system that weren't fully disentangled here.

Future research should explore whether maternal bile acid-lowering treatments during pregnancy can prevent these neonatal immune changes, and whether probiotic supplementation in high-risk infants could serve as a viable clinical preventative strategy.

Summary updated

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is a liver disease of pregnancy that is characterized by increased bile acid levels in maternal serum. Studies have shown that cholestatic pregnancy can result in long-term metabolic disturbances in the offspring. However, how ICP shapes the offspring's immunity and predisposition to inflammatory disorders at an early stage is unknown. In this study, we investigated the effect of maternal cholestasis on neonatal offspring metabolism and immune function. We compared 71 neonates with ICP mothers and 63 neonates with healthy mothers and found that the incidence of jaundice and infection was significantly higher in ICP offspring. Maternal serum total bile acid level was associated with blood cell counts in full-term ICP offspring. In animal experiments, a compensatory activation of hepatic and ileal farnesoid X receptor (FXR) and altered gut microbiota in the first week were found in ICP offspring. We also investigated lipopolysaccharide (LPS)-induced inflammatory responses in neonatal rats and found that ICP offspring were more susceptible to inflammation. To understand the correlation between congenital abnormal FXR activation and tissue immunity dysregulation, we assessed the effects of the FXR agonist GW4064 and FXR antagonist E/Z-GS in ICP offspring after LPS exposure. The expression of several pro-inflammatory cytokines significantly decreased after treatment with E/Z-GS but increased after treatment with GW4064. Treatment with the probiotic <i>Lactobacillus rhamnosus</i> LRX01 that inhibits FXR expression in the ileum reduced susceptibility to LPS exposure in ICP offspring. The current study indicated that cholestatic pregnancy may increase the susceptibility of the offspring to inflammation by altering bile acid metabolism and gut microbiota at an early stage. We suggest that supplementation with <i>Lactobacillus rhamnosus</i> LRX01, which inhibits FXR expression in the ileum, may improve intestinal immunity in ICP offspring.
BibTeX
@inproceedings{lin2022intrahepatic,
  author = {Qiongxi Lin and Wan-wen Huang and Wei Shen and Xiaoshi Deng and Ziyu Tang and Zhenhui Chen and Wei Zhao and Hongying Fan},
  title = {{Intrahepatic Cholestasis of Pregnancy Increases Inflammatory Susceptibility in Neonatal Offspring by Modulating Gut Microbiota}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.889646},
}
Figure